{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:01:50Z","timestamp":1784246510968,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T00:00:00Z","timestamp":1233532800000},"content-version":"vor","delay-in-days":2711,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item>\n<jats:p>Ezetimibe potently inhibits the transport of cholesterol across the intestinal wall, thereby reducing plasma cholesterol in preclinical animal models of hypercholesterolemia. The effect of ezetimibe on known absorptive processes was determined in the present studies.<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Experiments were conducted in the hamster and\/or rat to determine whether ezetimibe would affect the absorption of molecules other than free cholesterol, namely cholesteryl ester, triglyceride, ethinylestradiol, progesterone, vitamins A and D, and taurocholic acid. In addition, to determine whether exocrine pancreatic function is involved in the mechanism of action of ezetimibe, a biliary anastomosis model, which eliminates exocrine pancreatic function from the intestine while maintaining bile flow, was established in the rat.<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Ezetimibe reduced plasma cholesterol and hepatic cholesterol accumulation in cholesterol\u2010fed hamsters with an ED<jats:sub>50<\/jats:sub> of 0.04\u2003mg kg<jats:sup>\u22121<\/jats:sup>. Utilizing cholesteryl esters labelled on either the cholesterol or the fatty acid moiety, we demonstrated that ezetimibe did not affect cholesteryl ester hydrolysis and the absorption of fatty acid thus generated in both hamsters and rats. The free cholesterol from this hydrolysis, however, was not absorbed (92\u2003\u2013\u200396% inhibition) in the presence of ezetimibe. Eliminating pancreatic function in rats abolished hydrolysis of cholesteryl esters, but did not affect the ability of ezetimibe to block absorption of free cholesterol (\u221294%). Ezetimibe did not affect the absorption of triglyceride, ethinylestradiol, progesterone, vitamins A and D, and taurocholic acid in rats.<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Ezetimibe is a potent inhibitor of intestinal free cholesterol absorption that does not require exocrine pancreatic function for activity. Ezetimibe does not affect the absorption of triglyceride as a pancreatic lipase inhibitor (Orlistat) would, nor does it affect the absorption of vitamin A, D or taurocholate, as a bile acid sequestrant (cholestyramine) would.<\/jats:p>\n<\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2001) <jats:bold>134<\/jats:bold>, 409\u2013417; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0704260\">10.1038\/sj.bjp.0704260<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0704260","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T22:01:54Z","timestamp":1106949714000},"page":"409-417","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function"],"prefix":"10.1111","volume":"134","author":[{"given":"Margaret","family":"Van Heek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Hoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,2]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"156","article-title":"The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine","volume":"272","author":"BURRIER R.E.","year":"1995","journal-title":"J. Pharm. Exp. Ther."},{"key":"e_1_2_6_3_1","article-title":"The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors. (abstract)","author":"DAVIS H.R.","year":"1995","journal-title":"XII International Symposium on Drugs Affecting Lipid Metabolism (DALM)"},{"key":"e_1_2_6_4_1","first-page":"255A","article-title":"The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis (abstract)","volume":"35","author":"DAVIS H.R.","year":"2000","journal-title":"JACC"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199908000-00005"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)64849-5"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.8.1304"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/138161280301221005124721","article-title":"Established and emerging strategies for inhibition of cholesterol absorption","volume":"3","author":"HOMAN R.","year":"1997","journal-title":"Curr. Pharm. Des."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00548.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(01)80226-9"},{"key":"e_1_2_6_11_1","volume-title":"Third International Conference on Coronary Artery Disease\u2013from Prevention to Intervention","author":"KOSOGLOU T.","year":"2000"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)80612-7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1152\/ajplegacy.1957.190.2.214","article-title":"Role of pancreatic digestion in cholesterol absorption","volume":"190","author":"LIN T.M.","year":"1957","journal-title":"Am. J. Physiol."},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","unstructured":"LIPID: The Long\u2010Term Intervention with Pravastatin in Ischaemic Disease.(1998).Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N. Eng. J. Med. 339 1349\u20131357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_6_15_1","unstructured":"LIPKA L.J. LEBEAUT A.P. VELTRI E.P. MELLARS L.E. BAYS H.E. MOORE P.B.and the EZETIMIBE(SCH58235) STUDYGROUP(2000).Reduction of LDL\u2010cholesterol and elevation of HDL\u2010cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH58235): pooled analysis of two Phase II studies (abstract).JACC 35 257A."},{"key":"e_1_2_6_16_1","first-page":"229","article-title":"Atherosclerosis as a post\u2010prandial disease","volume":"2","author":"MAMO J.C.","year":"1995","journal-title":"Endocrin. and Metab."},{"key":"e_1_2_6_17_1","unstructured":"PHYSICIANS' DESKREFERENCE.(2000a).Colestid 54 2427\u20132430."},{"key":"e_1_2_6_18_1","unstructured":"PHYSICIANS' DESKREFERENCE.(2000b).Xenical 54 2693\u20132696."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00456-1"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm970701f"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","unstructured":"SCANDINAVIANSIMVASTATINSURVIVALSTUDYGROUP(4S).(1994).Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).Lancet 344 1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_2_6_24_1","first-page":"601","article-title":"Inhibition of post prandial fat absorption with the MTP inhibitor Bay 13\u20109952 (abstract)","volume":"102","author":"STEIN E.A.","year":"2000","journal-title":"Circulation"},{"key":"e_1_2_6_25_1","first-page":"258","article-title":"Effect of Bay 13\u20109952, a microsomal triglyceride transfer protein inhibitor on lipids and lipoproteins in dyslipoproteinemic patients (abstract)","volume":"100","author":"STEIN E.A.","year":"1999","journal-title":"Circulation"},{"key":"e_1_2_6_26_1","first-page":"S29","article-title":"Dietary cholesterol and the mechanisms of cholesterol absorption","author":"TURLEY S.D.","year":"1999","journal-title":"Eur. Heart J. Supplement"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.6.1330"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)00825-1"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703235"},{"key":"e_1_2_6_30_1","first-page":"157","article-title":"In vivo metabolism\u2010based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461","volume":"283","author":"VAN HEEK M.","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-2275(20)34751-9","article-title":"The effect of pancreatic diversion on lymphatic absorption and esterification of cholesterol in the rat","volume":"22","author":"WATT S.M.","year":"1981","journal-title":"J. of Lipid Res."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/41.1.153"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704260","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0704260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:55:10Z","timestamp":1695862510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0704260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1038\/sj.bjp.0704260"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0704260","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]},"assertion":[{"value":"2009-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}